Pathology-Based, Targeted Therapies—Managing Moderate-to-Severe Atopic Dermatitis in Adults
Lindsay C. Strowd, MD, FAAD
Assistant Professor of Dermatology
Wake Forest Baptist Health
This online activity is focused on the team involved in the management of adult patients with atopic dermatitis.
This online activity is intended for US-based dermatologists, allergists/immunologists, and primary healthcare professionals (physicians, nurse practitioners, and physician assistants) involved in the management of adult patients with AD.
Upon the completion of this program, attendees should be able to:
- Describe recent pathophysiological findings in AD that have informed the selection of new therapeutic targets
- Identify best practices for severity assessment and diagnosis of moderate-to-severe AD in adult patients, accounting for biomarkers, phenotype/genotype, comorbidities, and disease burden
- Review the clinical profiles and mechanisms of action of the new and emerging targeted biologic agents for the treatment of adults with AD
- Explain how different comorbidities and adherence barriers play a role in the choice of treatment regimens for adults with AD
- Discuss the benefits of patient-centered health care management teams for adults with AD and the respective roles of team members
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with atopic dermatitis.
Credits: 1.0 ANCC Contact Hour(s)
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Complete Conference Management will accredit this educational activity for 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Lindsay Strowd, MD, has received consulting fees from Sanofi Genzyme.
CME CONTENT REVIEW
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE CONTENT REVIEW
The content of this activity was peer reviewed by a nurse reviewer and the reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Cathy Herbert, VP Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: November 27, 2018
EXPIRATION DATE: November 27, 2019
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.